Idarubicin in patients with diffuse large cell lymphomas: A randomized trial comparing VACOP-B (A = doxorubicin) vs VICOP-B (I = idarubicin)

Haematologica

Volumn 82, Issue 3, 1997, Pages 309-313

  Bertini, Marilena ^a   Freilone, Roberto ^a   Botto, Barbara ^a   Calvi, Roberta ^a   Gallamini, Andrea ^b   Gatti, Anna Maria ^c   Liberati, Anna Maria ^d   Meneghini, Vittorio ^e   Orlandi, Ester ^f   Orsucci, Lorella ^a   Pizzuti, Michele ^g   Scalabrini, Delia Rota ^h   Salvi, Flavia ⁱ   Todeschini, Giuseppe ^e   Vitolo, Umberto ^a   Resegotti, Luigi ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b S CROCE E CARLE HOSPITAL   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

^e UNIVERSITY OF VERONA   (Italy)

^f FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^g SAN CARLO HOSPITAL   (Italy)

^h MAURIZIANO HOSPITAL   (Italy)

ⁱ C Arrigo Children's Hospital   (Italy)

Author keywords

Anthracyclines; Chemotherapy; Malignant lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; IDARUBICIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PROGNOSIS;

EID: 0031466916     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. McKelyey EM, Gottieb JA, Wilson HE, et al. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38:1484-93.
2. Coltman AC jr. CHOP is curative in thirty per cent of patients with large cell lymphoma: a twelve-year Southwest Oncology Group follow up. In: Skarin AT, ed. Update on treatment for diffuse large cell lymphoma. New York: Park Row, 1986. p. 71-7.
3. Fisher RI, De Vita VT jr, Hubbard SM, et al. Diffuse aggressive lymphoma: increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Intern Med 1983; 98:304-9.
4. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of advanced diffuse large cell lymphoma. Ann Intern Med 1985; 102:596-602.
5. Skarin AT, Canellos GP, Rosenthal DS, et al. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol 1983; 1:91-8.
6. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non Hodgkin's lymphoma. N Engl J Med 1993; 328:1002-6.
7. Vitolo U, Bertini M, Tarella C, et al. MACOP-B treatment for advanced stage diffuse large cell lymphoma. A multicenter Italian study. Eur J Cancer Clin Oncol 1989; 25:1441-9.
8. Vitolo U, Bertini M, Brusamolino E, et al. MACOP-B treatment in DLCL: identification of prognostic groups in an Italian multicenter study. J Clin Oncol 1992; 10, 2:219-27.
9. O'Reilly SE, Hoskins P, Klimo P, et al. MACOP-B and VACOP-B in diffuse large lymphoma and MOPP/ABV in Hodgkin's disease. Ann Oncol 1991; 22(suppl 1):17-23.
10. Bassan R, Lerede T, Rambaldi A, Buelli M, Viero P, Barbui T. The use of anthracyclines in adult acute lymphoblastic leukemia. Haematologica 1995; 80:280-91.
11. Bassan R, Barbui T. Remission induction therapy for adults with acute myelogenous leukemia: towards the ICE age? Haematologica 1995; 80:82-90.
12. Smith DB, Margison JM, Lucas SB, et al. Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin. Cancer Chemother Pharmacol 1987; 19:138-42.
13. The non Hodgkin's Lymphoma Classification Project. National Cancer Institute sponsored study of classification of NHL Summary and description of a working formulation for clinical usage. Cancer 1982; 49:2135-212.
14. Carbone PP, Kaplan HS, Mushoff K, et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31:1860-1.
15. Vitolo U, Cortellazzo S, Liberati AM, et al. Intensified chemotherapy followed by myeloablative therapy and autologous stem cell transplanation (ASCT) as first line therapy in high risk diffuse large cell lymphoma (DLCL). Blood 1995; 86:(suppl 1)458.
16. Jagannath S, Velasquez WS, Tucker SL, et al. Tumor burden assessment and its implications for a poor prognostic model in advanced diffuse large cell lymphoma. J Clin Oncol 1986; 4:859-65.
17. Shipp M. A predictive model for aggressive non Hogkin's lymphoma. The international non Hodgkin's lymphoma prognostic factors project. N Engl J Med 1993; 329:987.
18. Kaplan EL, Meier P. Non-parametric estimation from incomplete information. J Am Stat Assoc 1958; 53:457-81.
19. Freilone R, Vitolo U, Brusamolino E, et al. Late relapse and toxicities in advanced stage diffuse large cell lymphoma (DLCL) treated with MACOP-B: an eight year follow-up analysis. Ann Oncol 1996; 7:(suppl 2) 58.
20. Lambertenghi Deliliers G, Butti C, Baldini L, et al. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma. Haematologica 1995; 80:318-24.
21. Zinzani PL, Martelli M, Storti S, et al. Phase III Comparative Trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non Hodgkin's lymphoma. Leuk Lymphoma 1995; 19:329-35.
22. Keating MJ. The expanding role of idarabuctn in hematologic malignancies. Satellite Symposium "Emerging trends in the management of hematological malignancies" during the Second Meeting of the Euroepan Hematology Association, Paris, May 29, 1996.